Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color
Upeka Samarakoon, Santiago Alvarez‐Arango, Kimberly G. Blumenthal
Abstract
ing, Covid-19 had not developed in any of the patients after they received the three vaccine doses.No serious adverse events were reported after the administration of the third dose, and no acute rejection episodes occurred.This study showed that administration of a third dose of the BNT162b2 vaccine to solidorgan transplant recipients significantly improved the immunogenicity of the vaccine, with no cases of Covid-19 reported in any of the patients.However, a large proportion of the patients remain at risk for Covid-19.Barrier measures should be maintained, and vaccination of the relatives of these patients should be encouraged.
Topics & Concepts
ImmunogenicityCoronavirus disease 2019 (COVID-19)MedicineVaccinationAdverse effectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakIndigenousImmunologyVirologyInternal medicineOutbreakAntibodyEcologyBiologyDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchDermatological and COVID-19 studiesViral gastroenteritis research and epidemiology